- Home
- MPB vs PHAR Comparison
MPB vs PHAR Comparison
Compare MPB & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- PHAR
- Stock Information
- Founded
- MPB 1868
- PHAR 1988
- Country
- MPB United States
- PHAR Netherlands
- Employees
- MPB N/A
- PHAR N/A
- Industry
- MPB Major Banks
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- PHAR Health Care
- Exchange
- MPB Nasdaq
- PHAR Nasdaq
- Market Cap
- MPB 691.1M
- PHAR 951.7M
- IPO Year
- MPB N/A
- PHAR N/A
- Fundamental
- Price
- MPB $30.71
- PHAR $14.60
- Analyst Decision
- MPB Buy
- PHAR Strong Buy
- Analyst Count
- MPB 2
- PHAR 3
- Target Price
- MPB $34.50
- PHAR $30.00
- AVG Volume (30 Days)
- MPB 82.5K
- PHAR 12.7K
- Earning Date
- MPB 10-22-2025
- PHAR 10-23-2025
- Dividend Yield
- MPB 2.60%
- PHAR N/A
- EPS Growth
- MPB N/A
- PHAR N/A
- EPS
- MPB 2.30
- PHAR N/A
- Revenue
- MPB $191,454,000.00
- PHAR $339,836,000.00
- Revenue This Year
- MPB $24.57
- PHAR $16.63
- Revenue Next Year
- MPB $12.23
- PHAR $6.77
- P/E Ratio
- MPB $13.35
- PHAR N/A
- Revenue Growth
- MPB 13.34
- PHAR 22.44
- 52 Week Low
- MPB $22.50
- PHAR $7.31
- 52 Week High
- MPB $33.87
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- MPB 66.81
- PHAR 56.71
- Support Level
- MPB $29.94
- PHAR $13.63
- Resistance Level
- MPB $30.44
- PHAR $15.27
- Average True Range (ATR)
- MPB 0.60
- PHAR 0.96
- MACD
- MPB -0.02
- PHAR -0.13
- Stochastic Oscillator
- MPB 79.70
- PHAR 51.83
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.